Asthma Clinical Research Network (ACRN) Trial - Macrolides in Asthma (MIA)

Phase 3 Completed 92 enrolled Milton S. Hershey Medical Center National Heart, Lung, and Blood Institute (NHLBI) · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Asthma can be caused by a variety of factors, including tobacco smoke, allergens, and respiratory airway infections. Many people use inhaled corticosteroid medications to treat their symptoms. These medications, however, are not effective for everyone. Clarithromycin is an antibiotic that may effectively treat asthma in these individuals. This study will evaluate the effectiveness of clarithromycin at controlling asthma symptoms.

Timeline

Start: 2006-06
Primary completion: 2009-04
Completion: 2009-04

Outcome

Missed primary endpoint

paper This between-group difference of 0.3 ± 0.5 (P = .6) was neither clinically nor statistically significant. PMID 20920764 ↗

paper Adding clarithromycin to fluticasone in adults with mild-to-moderate persistent asthma that was suboptimally controlled by low-dose inhaled corticosteroids alone did not further improve asthma control. PMID 20920764 ↗

Publications

Results Sutherland ER, King TS, Icitovic N, Ameredes BT, Bleecker E, Boushey HA, Calhoun WJ, Castro M, Cherniack RM, Chinchilli VM, Craig TJ, Denlinger L, DiMango EA, Fahy JV, Israel E, Jarjour N, Kraft M, Lazarus SC, Lemanske RF Jr, Peters SP, Ramsdell J, Sorkness CA, Szefler SJ, Walter MJ, Wasserman SI, Wechsler ME, Chu HW, Martin RJ; National Heart, Lung and Blood Institute's Asthma Clinical Research Network. A trial of clarithromycin for the treatment of suboptimally controlled asthma. J Allergy Clin Immunol. 2010 Oct;126(4):747-53. doi: 10.1016/j.jaci.2010.07.024.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Clarithromycin	Small molecule	500 mg	—
Background	Fluticasone propionate	Other / unclassified	88 ug	Inhaled